Twist Bioscience Corporation Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Twist Bioscience Corporation (TWST) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $15.80 million for the 12-month period ending 2022-09-30, per its 10-K/A filed 2023-06-05.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2023-06-05
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2022-09-30 was $5.96M.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $15.80M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|
| 2022-09-30 | $5.96M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-05 | $15.80M 10-K/A · filed 2023-06-05 | |
| 2022-06-30 | $9.85M 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |